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Abstract
We have found that binding sites for interleukin-13 ( IL-
13) are overexpressed in a vast majority of high-grade
astrocytomas (HGAs). These binding sites for IL-13 are
distinct from the physiological receptor in that it does
not bind IL-4. We also demonstrated that IL-13 receptor
alpha 2 protein chain ( IL-13R2), an IL-4–independent
receptor for IL-13, is abundant among HGAs, but not in
normal organs. To examine if IL-13R2 is the tumor-
associated site for IL-13, we stably transfected normal
Chinese hamster ovary (CHO) cells and glioma G-26
cells to express either human (h) or murine (m) IL-
13R2. CHO-hIL-13R2( + ) cells and G-26-h /mIL-
13R2( + ) cells, and not CHO and G-26 parental or
mock-transfected cells, specifically bound IL-13 in an
IL-4–independent manner. The IL-13R2( + ) cells also
became highly susceptible to the killing by an IL-13–
based cytotoxic fusion protein. In loss of function
studies, a HGA cell line, SNB-19, was transfected with
antisense (as ) hIL-13R2. as -SNB-19-hIL-13R2( + )
cells lost their natural affinity towards IL-13 and became
resistant to IL-13–based cytotoxins. The fact, that IL-
13R2–positive cells bind IL-13 independent of IL-4,
become susceptible to IL-13 cytotoxins, and cells
deprived of IL-13R2 receptor lose these features,
demonstrates that IL-13R2 is the brain tumor–asso-
ciated receptor for IL-13.
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Introduction
High-grade astrocytomas (HGAs) are rapidly progressive
heterogeneous brain tumors of glial origin that are extremely
resistant to current therapies. Recently, we demonstrated
that the vast majority of HGAs bind interleukin-13 ( IL-13)
and are highly susceptible to the cytotoxicity of IL-13–based
cytotoxins [1–4].
IL-13 is an immune regulatory cytokine that shares a
variety of functions with IL-4 [5–7]. IL-13 is secreted by B
and T cells and binds to a plethora of different normal
hemopoietic and somatic cells [5–7]. Its physiological
functions are mediated through the shared IL-13/4 receptor
[8–11]. The IL-13/4 receptor is a heterodimer that first
binds IL-13 through the IL-13 binding component, IL-13
receptor alpha 1 ( IL-13R1) (42 kDa), at a low affinity and
subsequently recruits the IL-4 receptor component, IL-4R
(140 kDa) [11]. The complex of these two proteins results
in a high-affinity binding site for IL-13, which is competed
for by IL-4 [11,12].
We demonstrated that a vast majority of HGAs bind IL-13.
Unexpectedly, their affinity for IL-13 remained even in the
presence of IL-4 [1,3,13–15]. This indicated that there might
exist a more restricted HGA-associated receptor for IL-13
that is distinct from the physiological IL-13/4 receptor [4 ].
Additionally, mutants of IL-13 that showed a diminished
capacity to signal retained the ability to bind HGAs [14–16].
We demonstrated that a prototype mutant of IL-13, IL-
13.E13K, loses the ability to proliferate TF-1 cells, a
downstream effect of IL-13 signaling [15]. Furthermore, we
showed that IL-13.E13K competes for the HGA IL-13
binding site approximately 50 times better than wild- type
IL-13 [14]. These mutants were fused to derivatives of
Pseudomonas exotoxin (PE), such as PE38QQR, PE1E,
and PE4E, and showed ability to very potently kill glioma cells
[1,14,17]. Because these derivatives of PE lack a fully
functional 2 macroglobulin receptor binding domain of PE,
the only means the IL-13–based fusion protein can enter a
cell is through IL-13 binding to cell surface receptors and
subsequent internalization [12,13].
Additional experimental evidence for a second IL-13
receptor was provided by the work of Caput et al. [18]. These
investigators isolated a protein termed IL-13 receptor alpha
2 ( IL-13R2), which binds IL-13 in an IL-4– independent
manner, a feature resembling a glioma-restricted receptor
for IL-13. However, the link between IL-13R2 and the IL-
13 binding to the restricted sites on HGAs or the suscept-
ibility of HGA to IL-13–based cytotoxins did not appear to be
clear-cut. Several cell lines from which either the gene was
cloned or had tested positive for IL-13R2 gene expression
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did not demonstrate the anticipated response to IL-13-PE
cytotoxins (not shown). This and similar other initial lack of
correlation between IL-13R2 expression and, e.g., sus-
ceptibility to IL-13–based cytotoxins manifested the need to
further investigate whether or not IL-13R2 and the
restricted binding sites for IL-13 on HGA are in fact the
same IL-13 binding site.
Materials and Methods
Materials
DNA ligase and restriction endonucleases were pur-
chased from New England Biolaboratories (Beverly, MA).
Pfu turbo DNA polymerase was purchased from Stratagene
(La Jolla, CA). Oligonucleotide primers were synthesized in
the Macromolecular Core Laboratory of the Pennsylvania
State University College of Medicine. All polymerase chain
reaction (PCR) purifications, DNA extraction from agarose
gels, and plasmid minipreps were done using respective
Qiagen kits (Qiagen, Valencia, CA). Tissue culture equip-
ment was from Corning Glass (Corning, NY). RNA blotted
membranes were purchased from Clontech (Palo Alto, CA).
Cell lines, such as U-87 MG, SW-1088, H-4, A-431, U-
373 MG, SNB-19, and CHO-K1, were purchased from
American Type Culture Collection (Manassas, VA) or were
primary HGA cultures isolated in this laboratory (G-48a).
The ATCC CHO-K1 cell line was derived as a subclone
from the parental Chinese hamster ovary (CHO) cell line
initiated from a biopsy of an ovary of an adult Chinese
hamster. G-26 mouse glioma cells were the gift of
Dr. Marzenna Wiranowska.
Production of Recombinant Proteins
Plasmids and recombinant proteins for IL-13.E13K, IL-
13, IL-4, and IL-13.E13K-PE38QQR were prepared as
described in Debinski et al. [14 ] and Thompson and Debinski
[15]. The procedure used for protein production, isolation,
refolding, and purification of IL-13 and IL-13–based
cytotoxins was described previously [12].
RNA Isolation and Northern Blots
Total RNA from CHO, G-26, and SNB-19 cells were
obtained using an acid–guanidium isothiocyanate–phenol–
chloroform method [19]. Procedures for poly(A)+ isolation
and Northern blots were described previously [20]. Blots
were probed with random-primed 32P cDNA for hIL-13R2
or mIL-13R2. 32P riboprobes were also constructed as
described previously and used to probe for sense-strand
hIL-13R2. Additionally, blots were probed for actin to
demonstrate the integrity of the RNA.
Isolation of hIL-13R2 and mIL-13R2
hIL-13R2 was isolated by screening a cDNA library
derived from renal cell carcinoma (RCC) cells. A custom
cDNA library was prepared by Stratagene using poly(A)+
RNA isolated from the RCC cell line. The library was
screened using the protocol described by the manufacturer.
cDNA probes for hIL-13R2 were identical to the ones
described above.
mIL-13R2 was isolated from murine brain mRNA
obtained from Clontech. Superscript II Moloney murine
leukemia virus (MMLV) with a poly(T) primer was used to
synthesize first -strand cDNA. The resulting murine brain
cDNA was purified using a Qiagen PCR purification kit. For
PCR amplification of mIL-13R2, forward primer, 50 -CAGA-
CTAGGGGTACCATGGCTTTTGTGCAT-30, and reverse
primer, 50 -TGATGCTAGTCTAGATTAACAGAGGGTATC-
TTC-30, were used. Pfu turbo DNA polymerase was used
for high- fidelity amplification of mIL-13R2. KpnI and XbaI
restriction endonucleases were used to create compatible
ends and the resulting fragments were ligated into pcDNA
3.1 vector ( Invitrogen, Carlsbad, CA). Constructs were
sequenced in the Pennsylvania State University College of
Medicine Core Macromolecular Facility using an ABI 377
automated sequencer (PE, Norwalk, CT).
Transfection of CHO and G-26 Cells
The gene for hIL-13R2 that was transfected into CHO
cells was kindly provided by Dr. Pascual Ferrara of Sanofi
BioRecherche, Labe`ge Innopole (France) and the gene for
hIL-13R2 that was transfected into G-26 cells was isolated
by us. The primers used to PCR-amplify hIL-13R2 were
forward primer, 50 -AAGATTTGGGCTAGCATGGCTTTCG-
TTTGC-30, and reverse primer, 50 -TCCCTCGAAGCTT-
CATGTATCACAGAAAAA-30. For antisense constructs of
hIL-13R2, forward primer, 50 -AAGATTTGGAAGCTTATG-
GCTTTCGTTTGC-30, and reverse primer, 50 -TCCCTCG-
AAGCTTCATGTATCACAGAAAAA-30, were used and the
purified product was confirmed by sequencing. For the hIL-
13R2 forward construct, NheI and HindIII restriction endo-
nucleases were used to create compatible ends, and for the
antisense hIL-13R2 construct, HindIII restriction endonu-
clease was used. Fragments were ligated into pcDNA 3.1
vector.
DNA was transfected into CHO and G-26 cells using
lipofectin reagent as indicated by the manufacturer (Gib-
coBRL, Rockville, MD). After 48 hours, cells were pas-
saged 1:5 and grown in selection medium (800 g/ml
geneticin; GibcoBRL) until individual clones were isolated.
Cells were clonally expanded and maintained in 200 g/ml
geneticin.
Transfection of SNB-19 Cells with Antisense hIL-13R2
(as-hIL-13R2)
The construction of pcDNA3.1-as -hIL-13R2, which
contains the full - length gene of IL-13R2 in an antisense
orientation under a CMV promoter, is described above.
DNA was transfected into SNB-19 cells using lipofectin
reagent. In addition to geneticin, cells were selected in
media containing 10 g/ml IL-13–based cytotoxin, IL-
13.E13K-PE38QQR. This procedure efficiently helped
isolate clones expressing low amounts of hIL-13R2. IL-
13.E13K-PE38QQR was added to the SNB-19 cells
transfected with as - IL-13R2 48 hours after transfection
and surviving cells were maintained in media containing the
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cytotoxin for five passages. Additionally, mock- transfected
cells were treated with IL-13.E13K-PE38QQR in the same
manner as the transfected cells and no surviving clones
were observed.
Reverse Transcription (RT) PCR Analysis of IL-13R2
Gene Expression
RNA was isolated from CHO-IL-13R2( + ), G-26- IL-
13R2( + ) cells, and controls as described above and cDNA
was produced using Superscript reverse transcriptase from
GibcoBRL and Taq DNA polymerase. The sequence of
the primers used to specifically amplify 970 bp of cDNA
encoding hIL-13R2 was as follows: forward primer, 50 -
AGCTTGACCGCATATGTCATCTTCAGACACCGA-30, and
reverse primer, 50 -TGGTACGTGAGGTACCACGTAGCA-
AAGTTTTCT-30. To amplify a 900-bp fragment of murine
actin, forward primer, 50 -CAGAGCAAGAGGGGTATCC-
TGA-30, and reverse primer, 50 -TGATCCACATCTGCTG-
GAAGGT-30, were used. The primers used to amplify
mIL-13R2 were identical to the ones used to isolate the
gene.
Autoradiography
Recombinant IL-13 and IL-13.E13K were labeled
with 125I by using Iodo-Gen reagent (Pierce Chemical,
Rockford, IL) as described [1]. 5104 cells were dotted
onto sterile slides and allowed to adhere overnight.
Cells were then fixed using ice-cold ethanol. Procedure
used for autoradiography was previously described in
detail [1 ].
All films from autoradiography were scanned on a
transparency scanner at a pixel size of 8888 m (Molecular
Dynamics, Sunnyvale, CA) and the densities were plotted
using Quantity 1 software (Bio-Rad, Hercules, CA). The
images were compiled in Paint Shop Pro V 5.0 (Jasc
Software, Eden Prairie, MN).
Cell Proliferation Assay
Cytotoxicity assays were performed as described pre-
viously [14]. 3103 cells were plated in each well of a 96-
well plate in 150 l of media and allowed to adhere
overnight. The following day, 25 l of blocker (1 g/ml final
concentration) of IL-13.E13K, or IL-4 in 0.1% BSA/PBS
(phosphate-buffered saline) buffer, or buffer alone, was
added. After an hour of incubation at 378C, varying
concentrations of IL-13.E13K-PE38QQR were added in
triplicate and incubated at 378C in 5% CO2/95% O2 for
48 hours. After 48 hours, MTS/PMS cell proliferation assay
was performed as instructed by the manufacturer (Prom-
ega, Madison, WI). Ten microliters of dye was added to
each well and incubated for 4 hours. Plates were then read
by a microplate reader (Cambridge Technology, Watertown,
MA) at absorbance of 490 nm. Cyclohexamide- treated,
cell -containing wells served as the background for the
assay. Background was subtracted from each data point
and was divided by the value from the wells that were not
treated with cytotoxin to obtain the fraction of cells
remaining. The fraction of cells remaining was multiplied
by 100 to obtain the percent of control.
Production of Anti–hIL-13R2 Serum
A monoclonal antibody against IL-13R2, clone B-D13,
was purchased from Cell Sciences (Norwood, MA). This
antibody was found to be inadequate in our hands for
immunohistochemistry ( IH) and adequate for flow cytometry
in the presence of signal’s amplification. We therefore
commenced the production of anti– IL-13R2 serum in
house. One hundred micrograms of pcDNA3.1-hIL-13R2
DNA was injected intrasplenically into 10-week-old BALBc
mice and boosted 2 weeks later intramuscularly again with
100 g of the plasmid. Four weeks later, mice were
reboosted every other week for a total of three boosts with
500 g of affinity -purified 6 Histidine- IL-13R2 extrac-
ellular domain (6his-hIL-13R2ex) recombinant protein
produced in Escherichia coli. One week after the last
injection, serum was obtained.
IH
IH was performed on 1104 ethanol - fixed GBM cells or
snap- frozen sections of HGA tumors fixed to glass slides.
Samples were exposed to a 1:50 dilution of anti–hIL-13R2
serum or serum from an nonimmunized mouse. The
procedure used for immunostaining was described previ-
ously [21].
Cell ELISA Assay
1106 cells were plated in each well of a 96-well plate
and allowed to adhere overnight. Media were removed and
nonspecific binding sites were blocked using 2.5% dry milk
dissolved in media. After 20 minutes of blocking, 1:100
dilution of anti–hIL-13R2 serum or nonimmunized mouse
serum was added to each well for 30 minutes and shaken
gently at room temperature (RT). Cells were washed three
times with PBS and 1:1000 dilution of secondary antibody
(anti–mouse polyclonal alkaline phosphatase) (Roche,
Indianapolis, IN) was added for 30 minutes at RT. Cells
were washed three times with PBS and p -nitrophenyl
phosphate substrate was added (1 mg/1 ml) in alkaline
phosphatase buffer (100 mM NaCl, 5 mM MgCl2, 100 mM
Tris–HCl; pH 9.5) ( Invitrogen). Plates were then read
using a microplate reader (Cambridge Technology) at
absorbance of 405 nm. Values were obtained by subtract-
ing the background immunoreactivity observed in wells
treated with nonimmunized mouse serum. Each experiment
was performed in quadruplicates and repeated at least
twice.
Flow Cytometry
Cells were detached from flask using 1 PBS/4 mm EDTA
and counted using a hemocytometer. 1106 cells in a
volume of 100 l were stained for enhanced signal using
Flow-Amp enzymic enhancement kit (Flow-Amp Systems,
Cleveland, OH) according to the manufacturer’s instructions.
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Cells were incubated with anti–hIL-13R2 monoclonal
antibody (clone B-D13; Cell Sciences). Ten thousand
events (gated on viable cells ) were measured for each
sample and controls using a Becton Dickinson FACS scan
flow cytometer and analyzed with CellQuest software
(Becton Dickinson Biosciences, Franklin Lakes, NJ).
Results are expressed in mean fluorescence intensity
(MFI). Each experiment was repeated three separate times.
Results
HGA Tumor Specimens and Glioma Cell Lines are
Immunoreactive for hIL-13R2
Previously, we demonstrated that HGAs expressed the
transcript for hIL-13R2 [20]. Additionally, we demonstra-
ted that a vast majority of HGAs bind IL-13 independent of
IL-4 [1,3,13–15]. Here we demonstrate the presence of
immunoreactive hIL-13R2 on HGAs directly using anti–
hIL-13R2 mouse serum. Only the anti–hIL-13R2
serum, but not serum from nonimmunized mice, immunor-
eacted with the membranes of the HGA tumor section
(Figure 1A ).
IL-13R2 Immunoreactivity is Present in Brain Tumor Cells
To further document the presence of immunoreactive
hIL-13R2 in HGAs, various tumor cell lines were tested
using a cell ELISA assay. Because whole cells were used in
this assay, the only proteins that are exposed to the anti–
hIL-13R2 antibodies are plasma membrane proteins. Two
HGA cell lines, U-87 MG, U-373 MG, and one low grade
glioma cell line, H-4, all which are potently killed by IL-13–
based cytotoxins (Figure 1B ), demonstrated prominent
reactivity towards anti–hIL-13R2 serum (Figure 1C ). In
contrast, a HGA cell line, SW-1088, and an epidermoid
carcinoma cell line, A-431, both which are resistant to IL-
13–based cytotoxins (Figure 1B ), did not react with the
anti–hIL-13R2 serum (Figure 1C ). These results demon-
strate a link between the presence of IL-13R2 immunor-
eactive protein and the susceptibility of tumor cells to IL-13–
based cytotoxins.
Gain of Function Studies: Transfecting CHO and G-26 Cells
with hIL-13R2
In order to directly demonstrate that hIL-13R2 is the
glioma-restricted receptor for IL-13 and is responsible for
the restrictive IL-13 binding properties seen in HGAs, we
transfected normal CHO cells and murine glioma–derived
G-26 cells with hIL-13R2 in a CMV promoter-containing
vector.
Total RNA was isolated from clones that showed highest
transgene expression in the initial screening: CHO-hIL-
13R2( + ) clone 5 and G-26-hIL-13R2( + ) clone 2.
Then, Northern blot analysis was performed using 32P-
labeled hIL-13R2 cDNA. CHO-hIL-13R2( + ) clone 5
(Figure 2A, lane 3) and G-26-hIL-13R2( + ) clone 2
(Figure 2A, lane 6) demonstrated the presence of hIL-
13R2 transcript. Of importance, CHO and G-26 parental
clones (Figure 2A, lanes 1 and 4) and control clones
containing empty vector (Figure 2A, lanes 2 and 5) failed to
show any hybridization to 32P-hIL-13R2. Blots were also
probed with human 32P actin, which hybridizes to RNA
encoding murine actin as well (Figure 2A ). Additionally,
RT-PCR was performed to confirm the presence of
the transgene message using primers to specifically
amplify hIL-13R2. Only CHO-hIL-13R2( + ) clone 5
(Figure 2B, lane 3) and G-26-hIL-13R2( + ) clone 2
(Figure 2B, lane 6) and not the controls, such as G-26
and CHO parental cell lines (Figure 2B, lanes 1 and 4) or
G-26 and CHO transfected with empty vector (Figure 2B,
lanes 2 and 5), showed amplification of hIL-13R2 tran-
script. Murine actin was amplified to show the integrity of the
RNA in cells of murine origin (Figure 2B, lanes 4 to 7).
Transfecting mIL-13R2 into G-26 Murine Glioma Cells
In order to further analyze IL-13R2 in gliomas, a
murine glioma model that expresses IL-13R2 was
needed. Of the several rodent glioma cell lines that we
tested, all failed to demonstrate detectable levels of IL-
13R2 (unpublished). We therefore transfected mIL-
13R2 into the murine G-26 glioma cell line in order to
generate an immunocompetent syngeneic murine glioma
model that reflects the expression of IL-13R2 found in
human HGAs. mIL-13R2–transfected clones were ana-
lyzed using Northern blot analysis and RT-PCR. Northern
blot analysis of total RNA from mIL-13R2( + ) clone 17
and controls was performed using 32P- labeled mIL-13R2.
G-26-mIL-13R2( + ) clone 17 showed hybridization to
32P mIL-13R2 cDNA (Figure 2A, lane 7). In addition, RT-
PCR was performed on total RNA isolated from G-26-mIL-
13R2(+) clone 17. The resulting fragment of full - length
mIL-13R2 was demonstrated only in G-26-mIL-13R2(+)
clone 17 (Figure 2B, lane 7) and not in parental G-26
(Figure 2B, lane 4) or G-26 cells containing vector alone
(Figure 2B, lane 5).
CHO-hIL-132( + ) and G-26-hIL-13R2( + ) Cells
Specifically Bind IL-13 or its Mutant in an
IL-4–Independent Manner
IL-13.E13K is a mutant of IL-13 that has been shown to
have altered interactions with the physiological shared IL-
13/4 receptor, while preserving or even strengthening its
affinity towards the HGA-restricted IL-13 receptor [14–
16]. To examine the actual hIL-13R2 protein expression
and whether or not transgene-expressed hIL-13R2 is
capable of binding IL-13.E13K, iodo- labeled IL-13.E13K
was applied to ethanol - fixed cells and autoradiography was
performed. CHO and G-26 parental or mock- transfected
cells were not bound by the labeled cytokine (Figure 3,
column 1, 2, 4 and 5). However, in the absence of blocker,
CHO-hIL-13R2( + ) clone 5 (Figure 3, column 3) and G-
26-hIL-13R2( + ) clone 2 (Figure 3, column 6) showed
high retention of labeled IL-13.E13K. To ascertain that this
binding was IL-13 receptor–specific, an excess of unla-
beled IL-13.E13K was applied prior to 125I IL-13.E13K in
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Figure 1. (A ) hIL - 13R2 immunoreactivity in a GBM tumor specimen. Nonimmunized serum was used on a contiguous section of the same tumor as a negative
control. Tissues were also stained for nuclear presence using DAPI. (B ) Cytotoxicity of high - grade astrocytoma cells (SW-1088, U -373 MG, U -87 MG), low -
grade astrocytoma cells (H -4 ), and epidermoid tumor cells (A - 431 ) using 100 ng /ml IL - 13.E13K -PE38QQR determined in a colorimetric cell proliferation assay.
Vertical lines represent SD. (C ) Reactivity of high -grade astrocytoma cells (U -87 MG, U -373 MG, SW-1088 ), low -grade astrocytoma cells (H -4 ), and
epidermoid tumor cell ( A - 431 ) to anti –hIL - 13R2 serum in a cell ELISA assay. Vertical lines represent SD.
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a blocking assay. Efficient, more than 75% blocking of
labeled IL-13.E13K binding was observed in IL-13R2–
expressing clones (Figure 3, columns 3 and 6), indicating
that the binding of IL-13.E13K is an IL-13 receptor–
specific phenomenon. In addition, CHO-hIL-13R2–trans-
fected cells and controls were exposed to wild - type 125I
IL-13 in the presence and absence of excess IL-13. Only
CHO-IL-13R2( + ) clones and not parental or mock–
transfected CHO cells demonstrated retention of labeled
wild- type IL-13, which was competed for by excess IL-13
(not shown).
Unlike the physiological IL-13/4 receptor, the glioma-
restricted IL-13 receptor has the distinct characteristic of not
being competed for by IL-4 [1 ]. To determine whether hIL-
13R2 exhibits this property in our CHO-hIL-13R2( + ) and
G-26-hIL-13R2( + ) transfectants, we performed a com-
petition assay, applying unlabeled IL-4 prior to labeled IL-
13.E13K. As it was found on the majority of HGAs, no
significant blocking was observed in CHO-hIL-13R2( + )
clone 5 (Figure 3, column 3) and G-26-hIL-13R2( + )
clone 2 (Figure 3, column 6).
G-26-mIL-13R2( + ) Cells Specifically Bind IL-13.E13k in
an IL-4–Independent Manner
To examine if the functional characteristics of the IL-13
binding sites resulting from the presence ofmIL-13R2 in G-
26 cells are similar to those of hIL-13R2, autoradiography
was performed on G-26-mIL-13R2( + ) clone 17. In the
absence of blocker, G-26-mIL-13R2( + ) clone 17 avidly
bound labeled IL-13.E13K (Figure 3,AandB, column7). The
addition of unlabeled IL-13.E13K competed for the IL-13
binding sites on mIL-13R2( + ) cells, indicating IL-13–
specific binding (Figure 3, A and B, column 7). Furthermore,
cold IL-4 did not compete for the IL-13 binding sites on
G-26-mIL-13R2( + ) cells (Figure 3, A and B, column 7),
indicating that mIL-13R2 binds IL-13 independently of IL-
4, a characteristic of hIL-13R2.
CHO-hIL-13R2( + ) and G-26-hIL-13R2( + ) Clones
Become Highly Susceptible to Killing by IL-13–Based
Cytotoxins
HGAs demonstrate a high sensitivity toward IL-13–
based PE derivative-containing cytotoxins [11,14]. To
examine if CHO and G-26 cells, which are otherwise
resistant to IL-13–based cytotoxins (Figure 4, A and B ),
gain sensitivity towards IL-13–based cytotoxins when
transfected with hIL-13R2, we performed a colorimetric
cell proliferation assay. CHO-hIL-13R2( + ) cells, G-
26-hIL-13R2( + ) cells, and controls were exposed to
varying concentrations of IL-13.E13K-PE38QQR. The
hIL-13R2( + ) clones, CHO clone 5, and G-26 clone 2
became responsive to the cytotoxin, with IC50 values of 3 and
0.1 ng/ml, respectively, whereas parental and mock- trans-
fected CHO and G-26 cells remained resistant even in the
presence of up to 100 ng/ml cytotoxin (Figure 4, A and B ). In
addition, the susceptibility to IL-13–based cytotoxins varied
between hIL-13R2( + ) clones (Figure 4A for CHO-hIL-
13R2 clones 2 and 5, and Figure 4B ) for G-26-hIL-13R2
clones 2 and 5), suggesting that the cell killing is in
proportion to the amounts of hIL-13R2 transcript and
protein present. This was supported by Northern blot
analysis of CHO-hIL-13R2( + ) clone 2 that demonstrated
lesser amounts of hIL-13R2 mRNA than hIL-13R2( + )
clone 5 (not shown).
To determine if the susceptibility of hIL-13R2 express-
ing clones to cytotoxin is IL-4– independent and IL-13
Figure 2. (A ) Northern blot of CHO and G-26 cells transfected with hIL -13R2 or mIL - 13R2 and controls. Parental CHO cells ( lane 1 ), mock - transfected CHO
( lane 2 ), CHO-hIL -13R2( + ) clone 5 ( lane 3 ), parental G -26 cells ( lane 4 ), mock - transfected G-26 ( lane 5 ), G -26 -hIL - 13R2( + ) clone 2 ( lane 6 ), and G-
26 -mIL -13R2( + ) clone 17 ( lane 7 ) are shown. The size of transcripts is given in kilobases ( kb ). (B ) RT -PCR of hIL - 132 or mIL - 13R2 in G -26 and CHO
controls and transfected cells. The order of analyzed cells is the same as in (A ). The size of PCR-amplified fragments is given in kilobases ( kb ).
Neoplasia . Vol. 4, No. 5, 2002
Glioma-Restricted IL-13 Receptor Mintz et al. 393
receptor–mediated, a neutralization assay was performed
using an excess of IL-13.E13K. In the CHO-hIL-13R2( + )
and G-26-hIL-13R2( + ) clones tested, the killing by the
cytotoxin was completely inhibited in the presence of excess
IL-13.E13K but not IL-4 (Figure 4, C and D ).
mIL-13R2 Transgene Turns G-26 Murine Glioma Cells
into Responders to the hIL-13 Cytotoxin
In order to examine if a mIL-13R2 transgene changes
the G-26 cells’ responsiveness to IL-13–based cytotoxin,
the G-26-mIL-13R2( + ) clone 17 cells and controls
were treated with IL-13.E13K-PE38QQR. G-26-mIL-
13R2( + ) clone 17 and not the controls were killed by
IL-13–based cytotoxin at an IC50 of 0.1 to 1 ng/ml
(Figure 4E ). Excess IL-13.E13K neutralized the cell killing
by IL-13 cytotoxin in mIL-13R2–expressing cells,
whereas excess IL-4 had no effect on this phenomenon
(Figure 4E ).
IL-13R2( + ) Clones are Highly Susceptible to
IL-13–Based Cytotoxins Similar to HGA Cells
We demonstrated above that IL-13R2–transfected
cells became highly responsive to the killing by IL-13–
based cytotoxins. In order to juxtapose the susceptibility to
IL-13R2–transfected cells with human HGAs, HGA cell
lines SNB-19 and G-48a were treated with IL-13
Figure 3. (A ) Autoradiography of CHO-hIL - 13R2( + ) clone 5, G -26 -hIL - 13R2( + ) clone 2, G -26 -mIL - 13R2( + ) clone 17, and control cells using labeled
IL - 13.E13K. Parental CHO cells ( column 1 ), mock - transfected CHO (column 2 ), CHO-hIL -13R2( + ) clone 5 (column 3 ), parental G -26 cells ( column 4 ),
mock - transfected G-26 (column 5 ), G -26 -hIL - 13R2( + ) clone 2 ( column 6 ), and G-26 -mIL -13R2( + ) clone 17 ( column 7 ). The assay was performed in the
absence of blocker or in the presence of an excess of unlabeled IL -13.E13K or IL - 4. Each experiment was repeated at least four times and the results shown are a
representative sample of one of the experiments. (B ) Histogram of peak densities of 125I IL - 13.E13K binding in the absence or presence of IL - 13.E13K and IL -4 in
CHO-hIL -13R2( + ) clone 5, G -26 -hIL - 13R2( + ) clone 2, G -26 -mIL -13R2( + ) clone 17, and control cells. Column designations are the same as in (A ).
Measurements were taken from scanned X - rays shown in (A ).
394 Glioma-Restricted IL-13 Receptor Mintz et al.
Neoplasia . Vol. 4, No. 5, 2002
Figure 4. Cytotoxicity using IL -13.E13K -PE38QQR determined in a colorimetric cell proliferation assay. Vertical bars represent SD. (A ) CHO parental cells, CHO
mock - transfected, and CHO-hIL -13R2( + ) clones 2 and 5. (B ) G-26 parental cells, G -26 mock - transfected, and G-26 -hIL - 13R2( + ) clones 2 and 5. (C–E )
Neutralization assays in which the cell killing by IL - 13.E13K -PE38QQR in IL -13R2( + ) clones is blocked in the presence of an excess of IL - 13.E13K, but not IL -
4, in CHO and G-26 cells. ( F ) G -48a and SNB-19 HGA cells and neutralization of IL -13.E13K -PE38QQR cytotoxicity in the presence of an excess of IL -13.E13K,
but not IL - 4.
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cytotoxin. The two HGA cell lines were potently killed by
IL-13.E13K-PE38QQR at IC50 values of 0.01 to 0.1 ng/ml
(Figure 4F ), which is in a close range to what was seen in
IL-13R2–transfected cells. In addition, neutralization
assays were performed using an excess of mutated IL-
13, IL-13.E13K, but not IL-4, which blocked the cytotox-
icity of IL-13.E13K-PE38QQR in HGAs (Figure 4F ).
Loss of Function Studies: Transfecting SNB-19 Cells with
Antisense hIL-13R2
We demonstrated in gain of function studies that the
IL-13R2 transgene mimics the IL-13 binding properties
of HGA in that it 1) binds IL-13 independent of IL-4; 2)
binds a mutant of IL-13, IL-13.E13K; and 3) is able to
mediate the cytotoxicity of IL-13.E13K–based cytotoxins.
Figure 5. (A ) Northern blot of IL - 13R2 and actin in SNB-19mock - transfected, and as -SNB-19 -hIL - 13R2( + ) clones 1 and 6. (B ) IL -13R2 immunoreactivity
in SNB-19 cells transfected with as - IL -13R2 ( clones 1 and 6 ) and with vector only. DAPI nuclear staining was also performed. (C ) Flow cytometry performed on
SNB-19 parental cells and as -SNB-19 - IL - 13R2( + ) clone 6 cells. The bottom graph juxtaposes the distribution of the two experiments. Mean values of each
distribution are listed in the area under the peaks. Experiment was repeated three times.
396 Glioma-Restricted IL-13 Receptor Mintz et al.
Neoplasia . Vol. 4, No. 5, 2002
In order to demonstrate that IL-13R2, and not other
proteins, mediates these IL-13 binding properties in
HGAs, loss of function studies were performed. Antisense
hIL-13R2 was stably transfected into SNB-19 cells in a
CMV-containing vector. Clones containing low amounts of
hIL-13R2 were obtained by a previously described
method of selection in which IL-2–based cytotoxins had
been used to identify cell lines that were unable to
express high-affinity IL-2 receptors [22]. In our experi-
ment, an IL-13–based cytotoxin was used to select for
cells that had significantly reduced their expression level
of IL-13R2. Only as -SNB-19-hIL-13R2 transfectants,
but not the mock- transfected SNB-19 cells, survived this
selection. Total RNA was isolated from mock- transfected
SNB-19 cells, as -SNB-19-hIL-13R2( + ) clone 1, and
as -SNB-19-hIL-13R2( + ) clone 6, and Northern blot
analysis was performed. Mock- transfected SNB-19 cells
and not as -SNB-19-hIL-13R2( + ) clones showed
strong signal for the presence of hIL-13R2 gene
expression (Figure 5A ).
hIL-13R2 Protein Expression is Drastically Reduced in
as-SNB-19-hIL-13R2( + )–Transfected Cells
In order to demonstrate actual reduction in immunoreac-
tive IL-13R2protein expression inSNB-19 cells transfected
with as - IL-13R2, IH was performed using anti–hIL-13R2
serum. Mock- transfected SNB-19 cells demonstrated
intense immunoreactivity towards the anti–hIL-13R2
serum (Figure 5B ). In contrast, such immunoreactivity was
not seen in either of the as -SNB-19-hIL-13R2( + )
clones. Furthermore, flow cytometry performed on as -
SNB-19-hIL-13R2( + ) clone 6 using an anti–hIL-13R2
monoclonal antibody demonstrated a decreased amount of
hIL-13R2 expression compared to parental SNB-19 cells
(Figure 5C ).
as-SNB-19-hIL-13R2( + ) Clones no Longer Possess the
Restrictive IL-4–Independent IL-13 Binding Site
To examine if the IL-4– independent IL-13 binding sites
that are a characteristic of HGAs are still present in SNB-19
cells transfected with antisense hIL-13R2, autoradiography
Figure 6. (A ) Autoradiography and histogram of peak densities of IL -13 binding sites in SNB-19 parental cells, SNB-19 mock - transfected, and in as -SNB -19 -
hIL - 13R2( + ) clones treated with labeled IL - 13.E13K. Each experiment was repeated at least four times and the results shown are a representative sample of the
experiments. (B ) Cytotoxicity assay using IL -13.E13K -PE38QQR cytotoxin or wild - type PE in SNB-19 parental cells, SNB-19 mock - transfected, and in as -
SNB-19 -hIL - 13R2( + ) clones 1 and 6. Vertical bars represent SD.
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was performed. 125I - labeled IL-13.E13K was applied to as -
SNB-19-hIL-13R2( + ) clone 1, clone 6, and their controls.
Only parental and mock- transfected SNB-19 cells, but not
as -SNB-19-hIL-13R2( + ) clones, bound 125I - IL-13.E13K
(Figure 6A ).
as-SNB-19-hIL-13R2( + ) Clones Become Resistant to
the Killing by IL-13–Based Cytotoxins
We demonstrated that CHO and G-26 cells transfected
with IL-13R2 are susceptible to IL-13–based cytotoxins
similar to HGA cells. To examine if this susceptibility is truly
mediated by hIL-13R2 in human HGA cells, as -SNB-19-
hIL-13R2( + ) cells were treated with IL-13–based cyto-
toxins. Parental and mock- transfected SNB-19 cells were
characteristically killed by IL-13.E13K-PE38QQR, an IL-
13–based cytotoxin, at an IC50 of 0.01 to 0.1 ng/ml (Figure
6B ). Conversely, as -SNB-19-hIL-13R2( + ) clones 1 and
6 were no longer killed by IL-13.E13K-PE38QQR at
similarly low concentrations (Figure 6B ). Of importance,
as -SNB-19-hIL-13R2( + ) clone 6 failed to show suscept-
ibility to IL-13.E13K-PE38QQR at concentrations exceed-
ing 1000 times the IC50 of parental and mock- transfected
SNB-19 cells (Figure 6B ). To examine if this loss of
susceptibility to IL-13.E13K-PE38QQR was due to an
induced resistance of as -SNB-19-hIL-13R2( + ) cells to
PE, as -SNB-19-hIL-13R2( + ) clones and controls were
exposed to varying concentrations of wild - type toxin.
Because PE contains an 2 macroglobulin binding region,
its cytotoxicity is IL-13 receptor– independent. as -SNB-19-
hIL-13R2( + ) clones and controls were completely killed by
wild- type PE at all concentrations tested (Figure 6B ). This
result convincingly demonstrated that the resistance of as -
SNB-19-hIL-13R2( + ) clones to IL-13.E13K-PE38QQR
is due to the loss of IL-13 binding sites and not to an
inadvertently introduced resistance to PE.
Discussion
This study shows, for the first time, a direct link between IL-
13R2 and the IL-13 binding site properties seen in the vast
majority of HGAs. The gain of function studies using cells
transfected with hIL-13R2 demonstrate that hIL-13R2
binds IL-13 in an IL-4– independent manner, a character-
istic not found in nondiseased IL-13 binding cells. Moreover,
we demonstrate that a mutant of IL-13, which has altered
interaction with the shared IL-13/4 receptor, is bound by
hIL-13R2–expressing cells and internalized, a character-
istic feature of HGA-associated IL-13 binding. Importantly,
CHO cells and tumor G-26 cells became extremely
sensitive to IL-13.E13K-PE38QQR cytotoxin when trans-
fected with IL-13R2. IL-13.E13K-PE38QQR cytotoxic
fusion protein has been shown, in vitro and in vivo, to be
able to safely and efficiently treat HGA tumors [14].
Moreover, we showed for the first time that HGA cells
transfected with antisense hIL-13R2 1) lose an immunor-
eactive IL-13R2; 2) lose the restricted IL-4– independent
IL-13 binding site; and 3) become resistant to IL-13–based
cytotoxins. Thus, both gain of function and loss of function
studies provide direct evidence for the link between IL-
13R2 and the restricted IL-13 binding site seen in the vast
majority of HGAs.
Furthermore, we demonstrated that murine IL-13R2 can
mimic the restrictive IL-13 binding properties of human IL-
13R2 and can be used to generate a syngeneic, fully
immunocompetent murine HGA model that reflects the
presence and function of hIL-13R2 (Mintz et al., manu-
script in preparation). mIL-13R2 transfected into G-26
murine glioma cells caused the cells to bind IL-13.E13K in
an IL-4– independent manner and to become highly
susceptible to IL-13–based cytotoxins, characteristics of
cells containing hIL-13R2. This indicates a conserved
function between hIL-13R2 and mIL-13R2 and confirms
the absence of IL-13 species specificity between humans
and mice.
Recently, we demonstrated that the gene for hIL-13R2
is expressed in HGAs, but little, if at all, in normal tissue,
with the exception of the testes [20]. We therefore clas-
sified hIL-13R2 as a member of the cancer / testis antigen
(CTA) family. This finding, together with the direct evidence
provided in the current work that identifies IL-13R2 as a
Figure 7. Schemata of possible therapeutic interventions by using IL - 13R2 as a molecularly defined target.
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glioma-restricted receptor for IL-13, demonstrates the
potential of efficient and specific targeting of HGAs.
It is tempting to speculate that the expression of IL-
13R2 may be just one part of a more widespread
phenomenon in malignancy. Recently, a number of genes
located on chromosome X were found to be abnormally
expressed in cancer [23]. CTA are a group of antigens
located on the X chromosome and almost exclusively
expressed in cancer and the normal testes. It is plausible
that epigenetic pathomechanisms, such as abnormal meth-
ylation or aneuploidy, are responsible for the abundance of
CTAs in malignancy [23]. Of interest, IL-13R2 is only
sporadically present in low-grade astrocytomas and
becomes abundant only with the progression to higher -
grade malignancy [24,25]. Thus, its expression contributes
and/or reflects an important step in astrocytoma onco-
genesis.
Our previous and present studies, suggest that molec-
ular targeting of IL-13R2 is an attractive strategy for
molecular detection and treatment of HGAs (Figure 7).
Targeted gene therapy, targeted radiation, and targeted
chemotherapy all have the potential of being applied to
patients with HGAs. The evidence presented above sug-
gests that IL-13R2 is a unique molecular target to ac-
complish this goal.
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